AU2005223325B2 - Epothilone derivatives - Google Patents

Epothilone derivatives Download PDF

Info

Publication number
AU2005223325B2
AU2005223325B2 AU2005223325A AU2005223325A AU2005223325B2 AU 2005223325 B2 AU2005223325 B2 AU 2005223325B2 AU 2005223325 A AU2005223325 A AU 2005223325A AU 2005223325 A AU2005223325 A AU 2005223325A AU 2005223325 B2 AU2005223325 B2 AU 2005223325B2
Authority
AU
Australia
Prior art keywords
compound
formula
mmol
solution
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005223325A
Other languages
English (en)
Other versions
AU2005223325A1 (en
Inventor
Karl-Heinz Altmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2005223325A1 publication Critical patent/AU2005223325A1/en
Application granted granted Critical
Publication of AU2005223325B2 publication Critical patent/AU2005223325B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005223325A 2004-03-16 2005-03-15 Epothilone derivatives Ceased AU2005223325B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0405898.8A GB0405898D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0405898.8 2004-03-16
PCT/EP2005/002756 WO2005090335A1 (en) 2004-03-16 2005-03-15 Epothilone derivatives

Publications (2)

Publication Number Publication Date
AU2005223325A1 AU2005223325A1 (en) 2005-09-29
AU2005223325B2 true AU2005223325B2 (en) 2009-09-10

Family

ID=32117793

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005223325A Ceased AU2005223325B2 (en) 2004-03-16 2005-03-15 Epothilone derivatives

Country Status (11)

Country Link
US (2) US7825141B2 (enExample)
EP (3) EP2213670A3 (enExample)
JP (1) JP2007529455A (enExample)
KR (1) KR20070006773A (enExample)
CN (2) CN101805328A (enExample)
AU (1) AU2005223325B2 (enExample)
BR (1) BRPI0508874A (enExample)
CA (1) CA2556915A1 (enExample)
GB (1) GB0405898D0 (enExample)
RU (1) RU2006136089A (enExample)
WO (1) WO2005090335A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007016046A1 (de) 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4183099B2 (ja) * 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃおよびｄ、製造法ならびに組成物
DE19751027A1 (de) 1996-11-20 1998-05-28 Degussa Arylsubstituierte aminoacylierte Phosphonsäuren und deren Halbester
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
JP4434484B2 (ja) 1997-12-04 2010-03-17 ブリストル−マイヤーズ スクイブ カンパニー オキシラニルエポチロン化合物のオレフィン性エポチロン化合物への還元法
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19856128A1 (de) 1998-12-04 2000-06-15 Volkswagen Ag Verfahren und Einrichtung zum Lesen von Navigationsdaten
ES2207983T3 (es) * 1998-12-22 2004-06-01 Novartis Ag Derivados de epotilona y su uso como agentes antitumorales.
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
WO2003018002A2 (en) 2001-08-23 2003-03-06 Novartis Ag Cyclopropyl and cyclobutyl epothilone analogs
ATE452896T1 (de) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
ES2297189T3 (es) 2002-08-02 2008-05-01 Novartis Ag Derivados de epotilona.

Also Published As

Publication number Publication date
RU2006136089A (ru) 2008-04-27
KR20070006773A (ko) 2007-01-11
US20080114040A1 (en) 2008-05-15
CA2556915A1 (en) 2005-09-29
CN101805328A (zh) 2010-08-18
EP2213670A3 (en) 2010-11-24
EP1730138A1 (en) 2006-12-13
AU2005223325A1 (en) 2005-09-29
GB0405898D0 (en) 2004-04-21
US20110009459A1 (en) 2011-01-13
EP2213670A2 (en) 2010-08-04
CN1926133A (zh) 2007-03-07
BRPI0508874A (pt) 2007-09-04
EP2301940A1 (en) 2011-03-30
US7825141B2 (en) 2010-11-02
WO2005090335A1 (en) 2005-09-29
CN1926133B (zh) 2010-06-23
JP2007529455A (ja) 2007-10-25

Similar Documents

Publication Publication Date Title
EP1089998B1 (en) Epothilone derivatives and their synthesis and use
AU746597B2 (en) Epothilone analogs
CA2352505C (en) Epothilone derivatives and their use as antitumor agents
US20050192440A1 (en) Method for synthesizing epothilones and epothilone analogs
MX2012012227A (es) Derivado novedoso del acido hidroxamico.
RS51023B (sr) Derivati 6-alkenil, 6-alkinil i 6-epoksi-epotilona, postupak za njihovu proizvodnju i njihova upotreba u farmaceutskim pripravcima
NZ513268A (en) 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
JP5892620B2 (ja) ピラゾール誘導体
WO2004113281A1 (en) Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
MX2010011370A (es) Inhibidores de fosfatidilinositol 3-cinasa.
CZ20021531A3 (cs) Chinolinové a naftyridinové deriváty a karboxylové kyseliny
US7317100B2 (en) Epothilone derivatives
AU2005223325B2 (en) Epothilone derivatives
CN115403511B (zh) 荜茇酰胺类似物、药物组合物及其制备方法和应用
TW200404806A (en) Camptothecins with a modified lactone ring
CN113979850A (zh) 一种二萜衍生物及其制备方法、药物组合物和应用
MXPA06010415A (en) Epothilone derivatives
HU208019B (en) Process for producing alkoxy-methyliden-epi-podofillotoxin-glucosides and pharmaceutical compositions containing them
WO1986005784A1 (fr) Antibiotiques et preparation les contenant
JP2019506410A (ja) 抗癌剤インドテカンおよびインジミテカンのプロドラッグ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired